The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Matthew P. Goetz

Department of Oncology

Mayo Clinic

Rochester

Minnesota 55905

USA

[email]@mayo.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA. 2005 - 2011
  • Mayo Clinic College of Medicine, Department of Oncology, 200 First Street Southwest, Rochester, USA. 2004 - 2007

References

  1. Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials. Goetz, M.P., Schaid, D.J., Wickerham, D.L., Safgren, S., Mushiroda, T., Kubo, M., Batzler, A., Costantino, J.P., Vogel, V.G., Paik, S., Carlson, E.E., Flockhart, D.A., Wolmark, N., Nakamura, Y., Weinshilboum, R.M., Ingle, J.N., Ames, M.M. Clin. Cancer Res. (2011) [Pubmed]
  2. Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance. Goetz, M.P., Suman, V.J., Couch, F.J., Ames, M.M., Rae, J.M., Erlander, M.G., Ma, X.J., Sgroi, D.C., Reynolds, C.A., Lingle, W.L., Weinshilboum, R.M., Flockhart, D.A., Desta, Z., Perez, E.A., Ingle, J.N. Clin. Cancer Res. (2008) [Pubmed]
  3. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Goetz, M.P., Kamal, A., Ames, M.M. Clin. Pharmacol. Ther. (2008) [Pubmed]
  4. Aromatase inhibitors and tamoxifen: where do we go from here? Goetz, M.P., Loprinzi, C.L. Nat. Clin. Pract. Oncol (2007) [Pubmed]
  5. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Goetz, M.P., Knox, S.K., Suman, V.J., Rae, J.M., Safgren, S.L., Ames, M.M., Visscher, D.W., Reynolds, C., Couch, F.J., Lingle, W.L., Weinshilboum, R.M., Fritcher, E.G., Nibbe, A.M., Desta, Z., Nguyen, A., Flockhart, D.A., Perez, E.A., Ingle, J.N. Breast Cancer Res. Treat. (2007) [Pubmed]
  6. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Goetz, M.P., Suman, V.J., Ingle, J.N., Nibbe, A.M., Visscher, D.W., Reynolds, C.A., Lingle, W.L., Erlander, M., Ma, X.J., Sgroi, D.C., Perez, E.A., Couch, F.J. Clin. Cancer Res. (2006) [Pubmed]
  7. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. Goetz, M.P., Rae, J.M., Suman, V.J., Safgren, S.L., Ames, M.M., Visscher, D.W., Reynolds, C., Couch, F.J., Lingle, W.L., Flockhart, D.A., Desta, Z., Perez, E.A., Ingle, J.N. J. Clin. Oncol. (2005) [Pubmed]
  8. Developments in combination chemotherapy for colorectal cancer. Goetz, M.P., Grothey, A. Expert. Rev. Anticancer. Ther (2004) [Pubmed]
 
WikiGenes - Universities